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 Abstract 
Recent advances in genetics and genomics have revealed new genes and pathways that are somatically altered 
in human malignancies. This wealth of knowledge has translated into molecularly defined targets for therapy 
over the past two decades serving as key examples that translation of laboratory findings can have great impact 
on the ability to treat patients with cancer. However, given the genetic instability and heterogeneity that are 
characteristic of all human cancers, drug resistance to virtually all therapies have emerged posing further and 
future challenges for clinical oncology. Here we review the history of targeted therapies, including early 
concepts with endocrine therapies for hormonally driven cancers and more contemporary examples of 
genetically defined cancer targets and their approved therapies. We will also discuss resistance mechanisms that 
have been uncovered with an emphasis on somatic genetic alterations that lead to these phenotypes.  
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Endocrine Therapies: The first “targeted” therapies 
Anti-Estrogens 
 The very first examples of target-specific cancer therapies were developed as endocrine or hormone 
therapies for certain cancers including breast and prostate cancers as well as for the M3 subtype of acute 
myeloid leukemia now known as acute promyelocytic leukemia.  It is now well-established that estrogen 
receptors (ER) have been linked to breast cancer development and in particular ERα is now widely accepted to 
have a functional role in many breast cancers (1). ERα and ERβ are steroid hormone receptors belonging to the 
nuclear receptor superfamily (2). In normal breast epithelial cells, the estrogen receptors function as ligand-
activated transcription factors to stimulate proliferation in response to estrogen. Additionally, the estrogen 
receptors can stimulate growth pathways through interaction with G-protein coupled receptors. Nearly 75% of 
all breast tumors express ERα, often at high levels compared to normal epithelium. These ER-positive cells are 
said to be estrogen dependent as they are known to regress if hormone is removed or blocked. This phenomenon 
was first discovered when it was noticed that the removal of the ovaries could lead to regression of many breast 
tumors. This observation led the drive to develop ER antagonists as a way to selectively target ER-positive 
breast cancers. 
 Tamoxifen, a compound synthesized in the late 1960s, was originally designed as a contraceptive and 
was one of the earliest anti-estrogens to be tested as a cancer therapeutic (3)(4). Following FDA approval in 
1977, tamoxifen eventually became a widely accepted treatment for ER-positive breast cancers. In ER-positive 
breast tissue, tamoxifen binds to ER and forms a nuclear complex that competitively inhibits the action of 
estrogen.  Additionally, it can recruit co-repressors in these tissues and downregulate transcriptional activity of 
proliferative genes whose expression is regulated by ER. Paradoxically, tamoxifen has been shown to act as an 
estrogen agonist in other cell tissues, such as bone and uterine tissue. In this case the tamoxifen-ER complex 
recruits co-activators increasing the gene expression of growth promoting ER regulated genes. Tamoxifen, and 
compounds of similar action, have been classified as SERMs (Selective Estrogen Receptor Modulators). It is 
this ability to selectively act as an estrogen receptor agonist or antagonist in differing tissue types that 
distinguishes this class of therapies. 
 Upon its approval for clinical use, tamoxifen displayed great promise as a targeted therapy against ER 
positive breast cancers. Unlike traditional cancer treatments that target all proliferating cells, tamoxifen inhibits 
the proliferation of estrogen dependent breast cells only. Moreover, because it antagonizes and/or mimics the 
action of a natural steroidal hormone, the side effects of tamoxifen are relatively well tolerated compared to 
traditional chemotherapies and radiation treatments. The success of tamoxifen brought about the development 
of many other SERM or SERM-like compounds. These include raloxifene, toremifene, lasofoxifene and others. 
However, despite its widespread use and significant success, tamoxifen-resistance (and resistance to the other 
SERMS) is a common occurrence. Many mechanisms of tamoxifen resistance have been described including 
change of tamoxifen’s response from antagonism to agonism (5), and/or through activation of alternative 
growth pathways such as EGFR or HER mediated MAP Kinase and PI3 Kinase pathway signaling. 
Nevertheless, tamoxifen remains as a standard of care treatment for many patients.  
 Over the past decade, fulvestrant, a non-SERM anti-estrogen drug, has been developed and approved for 
the treatment of metastatic ER-positive breast cancer. Fulvestrant is an ER antagonist that, similar to SERMs, 
competitively binds to ER and acts to antagonize estrogen signaling. Fulvestrant is unlike SERMs in that it does 
not have mixed agonistic properties. Moreover, once bound to ER, fulvestrant pharmacologically induces ER 
degradation. Likely due to its different mechanism of action, fulvestrant has been shown to be effective in a 
large percentage of women with tamoxifen-resistant breast cancer (6). However, resistance to fulvestrant is still 
prevalent, most likely due to activation of alternative growth pathways, including aberrant EGFR and HER2 
signaling (7). 
 Another class of endocrine therapies, known as aromatase inhibitors was developed at the turn of the 
21st century. These compounds work by blocking the action of aromatase, an enzyme that mediates the 
synthesis of estrogens from other steroid precursors. The main source of circulating estrogen in premenopausal 
women is production by the ovaries which is non-aromatase mediated.  In contrast, aromatization of androgens 
is the primary source of estrogen in post-menopausal women. Aromatase inhibitors act to inhibit the final steps 
of the catalysis of androtestosterone into estrone, and testosterone into estradiol, thus decreasing the levels of 
circulating estrogen in patients. Clinically approved aromatase inhibitors include the steroidal inhibitor 
exemestane and the non-steroidal inhibitors anastrozole and letrozole. While these compounds can effectively 
block nearly 99% of all aromatase enzymatic activity and lead to marked decreases of estrogen levels in patents, 
between 30-70% of patients will develop clinical resistance to AI therapy (8)(9). Like SERM resistance, 
resistance to aromatase inhibitors is thought to be linked to changes in estrogen dependence and activation of 
alternative growth pathways (9). In fact, the similarities in resistance to both classes of endocrine therapies are 
exemplified by the cross-resistance often seen clinically in patients with progressive disease. Interestingly, ER 
mutations have rarely been seen as a mediator of resistance to endocrine therapies. 
Anti-Androgens 
 Like ER and breast cancer, the link between androgens and prostate cancer has been appreciated for 
many years. In fact, this correlation was first described in 1941 when it was acknowledged that patients who 
underwent surgical or medical castration often displayed significant regression of their metastatic disease 
(10)(11). This discovery led to early crude attempts to block androgen production through the use of estrogen 
and estrogen agonists (12). An increase in estrogen inhibits LHRH (luteinizing hormone-releasing hormone), 
thereby decreasing testosterone production. The search for more refined anti-androgen therapies led to the 
development and approval of bicalutamide in the mid-1990’s (13)(14). 
 Bicalutamide, and similar therapies such as flutamide and nilutamide, are non-steroidal anti-androgens. 
Similar to the mode of action of tamoxifen on ER, these drugs block the androgen receptor (AR) though 
competitive inhibition. Comparable to hormonal treatment for breast cancer, anti-androgens also can act to 
either inhibit or stimulate the AR depending on the cellular context of the cell. As has been described for 
endocrine therapy in breast cancer, it is well known that withdrawal of anti-androgen treatment in resistant 
tumors can lead to significant tumor regression (15). The genetic/genomic mechanisms of this are only now 
being elucidated.  
 Additional effective endocrine therapies for prostate cancer include the class of drugs known as LHRH 
agonists. These drugs include leuprolide and goserelin, and are thought to act as agonists on the pituitary-
gonadal axis leading to suppression of LHRH through negative feedback, but may also act as antagonists to 
LHRH production directly (12). Newer iterations of anti-androgens with proven efficacy include enzalutamide, 
which blocks AR action by inhibiting nuclear re-localization and DNA-binding, and abiraterone which inhibits 
testosterone production (15)(16). However, similar to other hormonal therapies, the dual antagonistic and 
agonistic nature of these drugs, along with alternative growth signaling pathways likely contributes to a high 
incidence of resistance. Interestingly, unlike ER and endocrine therapy resistance, mutations that could lead to 
anti-androgen therapeutic resistance have been reported (17,18).  
Retinoids 
 Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia in that all cases 
are defined by abnormal translocations of retinoic acid receptor (RARα), generally occurring between the 
RARα and PML genes on chromosomes 15 and 17 [t(15;17)], respectively (19). RARs are ligand-dependent 
nuclear transcription factors that interact with several promoter response elements (RAREs) throughout the 
genome (20). When bound to retinoids, such as vitamin A, RARs dimerize with retinoid X receptors (RXRs) to 
transcriptionally regulate expression of genes involved in growth, vision, reproduction, embryonic 
development, differentiation of epithelial tissues, and immune responses (21). The abnormal expression patterns 
and unusual presence of RARα fusion proteins in APL sparked interest in targeting this pathway for therapy. In 
1988, all-trans retinoic acid (ATRA) was proven to be a successful treatment for APL patients (22)(23). With 
further refinements in optimal dosing and combination with newer agents, the majority of APL patients 
undergoing ATRA treatment achieve clinical remission and have favorable long term outcomes (24). 
Unfortunately, acquired resistance to ATRA and remission can still occur and is thought to be caused by 
changes in retinoid clearance, increased retinoid sequestration or mutational changes in the PML-RARα fusion 
gene (20). 
First Generation Targeted Therapies 
 The success of endocrine therapies hinted at the potential of having more refined compounds that 
selectively inhibited cancer cells. While hormonal therapies utilize natural pathways to inhibit receptor 
mediated growth responses, the nature of these systemic treatments and expression of steroid receptors on other 
normal cell types yielded predictable side effects. However, the benefit of endocrine therapies is derived from 
the fact that hormone receptors are only expressed in the tumor cells and a limited number of normal cells and 
tissues, resulting in tolerable side effects along with anti-cancer efficacy. Importantly, the number of cancers 
that are amenable to nuclear hormone receptor targeted therapies is limited, as only a few cancer types utilize 
these pathways for cell growth and proliferation. Therefore, the development of other drugs distinct from 
nuclear hormone receptors would herald the modern era of truly targeted therapies for human cancers, though 
not without significant challenges. 
Multi-Kinase Inhibitors 
 The first and undoubtedly most famous drug that revolutionized the concept of small molecule kinase 
inhibitors was imatinib (STI571, Gleevec, Glivec). Imatinib was originally developed in the late 1990’s and was 
the result of many peoples’ work.  Notably, Brian Druker demonstrated its value as a targeted therapy against 
the BCR-ABL protein expressed in the vast majority of chronic myelogenous leukemia (CML) patients 
(reviewed in (25)). Imatinib was discovered as part of a panel of small molecule inhibitors designed to target the 
BCR-ABL tyrosine kinase. CML develops from the reciprocal translocation between chromosomes 9 and 22, 
leading to the “Philadelphia chromosome” (Ph+) which is a genetic hallmark of this disease (26)(27). This 
translocation creates the BCR-ABL fusion gene product encoding for a hyper-activated ABL tyrosine kinase. 
This unique molecular prolife presented itself as an ideal target for therapy. Specifically, inhibition of ABL 
kinase activity would, in theory, specifically deter the proliferation of the malignant Ph+ clonal cancer cells, yet 
non-CML cells would not be affected. Imatinib was one of many small molecule inhibitors biochemically 
designed with this function in mind.  High-throughput screening against protein kinase C (PKC) activity teased 
out imatinib as having high potential for pharmacologic inhibition (25). The success of imatinib for treating 
CML was widely viewed as a remarkable triumph for targeted cancer therapies. Prior to the use of imatinib, 
only 30% of CML patients survived 5 years after diagnosis. After FDA approval of imatinib in 2001, this 
percentage has steadily risen to nearly 90% (28). 
 Imatinib acts by blocking the kinase activity of the BCR-ABL protein. Specifically, imatinib occupies an 
area of the ATP-binding pocket of ABL, locking it in the inhibited or closed confirmation (29). In this way, the 
normally constitutively active BCR-ABL kinase is turned off and it can no longer phosphorylate downstream 
targets. This elegant mechanism of action leads to tumor cell senescence and apoptosis, through the down 
regulation of BCR-ABL mediated growth promoting proteins including RAS, SRC, PI3K and JAK/STAT. 
However, imatinib is not as specific to BCR-ABL as originally thought. It has proven to be an inhibitor to other 
kinases, most notably c-Kit and PDGFR(28). This promiscuity in hindsight, is in fact advantageous, as imatinib 
has proven to be an effective treatment for gastrointestinal stromal tumors (GIST) which exhibit mutated c-KIT 
or activated PDGFR (30).  
 Although an undeniable success story, at least 10% of patients will not demonstrate prolonged benefit 
from imatinib therapy (31). This can be due to initial resistance upon treatment or an acquired resistance after 
an initial response to the drug. Several mechanisms for innate and acquired resistance to imatinib have been 
proposed. Amplification or duplication of the BCR-ABL kinase, c-KIT or PDGFR may be one such mode of 
resistance, in which the increased tyrosine kinase production outcompetes the action of the drug (31)(32). 
Importantly, point mutations in the ABL gene have also been linked to imatinib resistance, most frequently a 
threonine to isoleucine substitution (T315I) in the kinase domain that prevents imatinib association with the 
ATP-binding pocket (31–33). Not only do these mutations confer resistance to imatinib treatment, but they also 
exhibit increases in cancerous phenotypes (34). Many other mutations of the ABL gene have been identified as 
contributing to resistant phenotypes including mutations within the P-loop, SH2 domain, A-loop, C-helix and 
substrate binding domain (31). Mutations in c-KIT and PGDFR are also associated with imatinib resistance in 
GIST patients (32). Alternative mechanisms of imatinib resistance have also been described and include 
changes in drug influx/efflux, epigenetic modification and activation of alternative growth pathways 
independent of tyrosine kinase receptors (31,32). 
 Following the success of imatinib in treating CML and GIST, the race to replicate these results with 
similar kinase inhibitors to benefit other forms of cancers began in earnest. There were many compounds that 
were developed and approved as a result of this new areas of focus, including several compounds that similar to 
imatinib, target several different kinases. Sorafenib and sunitinib are two such compounds. These drugs have 
shown to inhibit various growth signaling pathways involved with a number of receptor tyrosine kinases, as 
well as VEGFR-dependent angiogenesis (35). In a manner similar to but distinct from imatinib and ABL kinase, 
sorafenib and sunitinib interact with the ATP-binding pocket within the kinase domain of their respective 
targets, competitively deactivating the growth signaling of the various kinases (36,37). Originally approved for 
clinical use in 2006, sorafenib is a small molecule inhibitor of VEGFR, PDGFR and the RAF kinases CRAF 
and BRAF. Originally, designed as a RAF kinase inhibitor, sorafenib has been utilized as a successful treatment 
for renal and liver cancers (36,38). Sunitinib was approved in 2006 for renal cell carcinoma and GIST, and has 
been shown to target VEGFR, PDGFR, KIT, RET, FLT3 and other receptor tyrosine kinases (35,39–43). 
Sunitinib inhibits c-KIT and PDGF in a manner distinctly different than imatinib, and therefore it is clinically 
used with some success for the treatment of imatinib resistant GIST (44).  Although in theory, the multi-kinase 
inhibition of these molecules might reduce the emergence of drug resistance, in practice resistance to sorafenib 
or sunitinib is common.  In addition, the multi-kinase inhibitory properties also make these drugs less selective 
for cancer cells resulting in numerous side effects for most patients.  Resistance can arise to either or both the 
anti-proliferative and anti-angiogenic properties of these kinase inhibitors. Activation of alternative signaling 
pathways (AKT, PI3K, etc.), drug sequestration, upregulation of non-VEGF dependent angiogenesis factors 
(FGF, IL8, etc.), and pro-angiogenic pericyte and monocyte recruitment are some of the documented 
mechanisms of resistance to PDGFR and VEGFR inhibitors including sorafenib and sunitinib (32,45,46). 
Although these drugs are effective for certain indications, their lack of specificity and toxicity profiles dictated 
further refinements in targeted therapies for cancer.  
mTOR Inhibtors 
 The mammalian target of rapamycin (mTOR) has proven to be a much sought after target in drug 
development. It is a regulator of cell signaling found downstream of several growth pathways that are mutated 
in cancers including the PI3K/AKT signaling cascade.  As the name suggests, mTOR was discovered as a target 
for the anti-fungal rapamycin in yeast cells (47–49). Rapamycin interacts with the protein FKBP12 (Rbp1) 
forming a complex that then binds the FRB (FKB) domain of mTOR, thereby inhibiting mTOR kinase activity 
and mTOR substrate interaction (50)(51). mTOR associates with two proteins; RAPTOR and RICTOR, forming 
two complexes mTORC1 and mTORC2, respectively(48)(51). Rapamycin predominantly interacts with 
mTORC1-RAPTOR and inhibits the phosphorylation of the targets S6 kinase 1 (S6K1, p70) and eukaryotic 
initiation factor 4E binding protein (4EBP1) (52,53).  
 The pursuit of mTOR inhibitors as an anti-cancer therapy first gained traction with the discovery of the 
rapamycin analogs (rapalogs) temsirolimus, everolimus and ridaforolimus (deforolimus). Like rapamycin, the 
rapalogs target FKBP-12 rapamycin binding domain (FRB, FKB) of the mTORC1 complex (52,53). Unlike 
rapamycin these rapalogs do not have the same degree of immunosuppressive properties, and as a result exhibit 
lower infection related toxicity. Temsirolimus and everolimus are prodrugs, such that their metabolites are the 
active rapamycin-like forms. These compounds inhibit several downstream targets of mTOR such as HIF1α, 
cyclin D and VEGF thereby affecting angiogenesis, cell proliferation, cellular metabolism, and survival (54). 
Temsirolimus, the first rapalog to be approved for clinical use, is primarily administered for the treatment of 
renal cancer. In the past few years, everolimus has been approved for the treatment of kidney, pancreatic and 
ER positive, HER2-negative breast cancers.   
 mTOR remains a promising target for cancer treatments, as it can control many tumorigenic factors such 
as angiogenesis, proliferation, survival etc. However, it is this role as a regulator of such a diverse range of 
functions that allows rapalog resistance to arise by many different mechanisms.  One source of resistance is due 
to the fact that the rapalogs depend on the interaction with FKBP-12 for activity. Mutations in FKBP12 or the 
FKBP12 binding domain of mTORC1 can result in rapalog resistance due to a drop in binding affinity (55–57). 
Additionally, alternative proliferative signaling cascades can be activated in response to negative feedback from 
mTOR targets. Upregulation of PI3K, AKT, MAPK, PIM kinase and PDK activity has been observed in 
response to rapamycin and rapalog treatment (58–60). This mechanism of resistance is common among targeted 
therapies, that is, when one signaling pathway of proliferation or survival is disrupted, alternative pathways 
become activated by negative feedback loops. This mechanism of resistance is especially vexing with the 
rapalogs because mTORC2 will phosphorylate AKT at serine 473 in response to negative feedback from 
mTORC1 inhibition (61). The expression patterns of the targets of mTOR can also become altered and thereby 
cause rapalog resistance. Decreases in 4E-BP1 protein levels can confer resistance to rapalogs, and increased 
expression of eIF4E can also lead to resistance (62,63). Rapalogs are believed to cause apoptosis by stimulating 
the release of cytochrome c thereby initiating the mitochondrial caspase9/caspase3 apoptotic pathway. Thus, 
increases in anti-apoptotic signals, through upregulation of Bcl-2 or the IAPs, has been indicated to contribute 
to rapalog resistance (64,65). Inhibition of mTOR also decreases HIF-1α expression, a protein that controls 
VEGF transcription, and therefore it is proposed that inhibition of HIF-1α by rapalogs can trigger decreases in 
angiogenesis and limit tumor growth (65,66). Accordingly, activation of alternative angiogenesis signals can 
bypass this component of the anti-tumor effect of rapalogs and contribute to decreased effectiveness of these 
compounds.  
 Several strategies are being pursued to overcome rapalog resistance in cancers. Second generation 
mTOR inhibitors (mTOR Kinase inhibitors) are being developed that competitively inhibit the serine/threonine 
kinase activity of mTOR (67). The advantage of this mode of mTOR inhibition is that it is independent of 
FKBP12 and targets both mTORC1 and mTORC2. Another potential method to overcome the common causes 
of rapalog resistance is treatment with rapalogs together with compounds that target alternative proliferative 
pathways such as the PI3 Kinase and/or MAP Kinase pathways.  Furthermore, single compounds that block 
both PI3K and mTOR are being explored for improved efficacy (67)(68). Thus, mTOR remains a desirable 
target for many cancer therapies. 
Current and Future Cancer Targeted therapies 
CD20 and rituximab 
 Antibodies have always held high promise as targeted therapies due to their potential specificity and 
presumed lack of toxicity. They are naturally designed to only interact with their target proteins and therefore 
present a low likelihood for serious side-effects (depending on the target protein). One of the first and most 
successful antibodies in cancer therapy is rituximab, a monoclonal antibody (mAb) against the B-cell antigen 
CD20. CD20, initially described in 1980, is a member of the membrane-spanning 4-A (MS4A) family of 
proteins (69–72). CD20 plays an important role in B-cell-to-plasma differentiation; it is expressed exclusively 
in pre-B cells and developing B-cells and its expression is lost in plasma cells. The clinical significance of this 
protein was quickly realized upon the observation that CD20 is highly expressed in B-cell lymphomas, hairy 
cell leukemias and B-cell chronic lymphocytic leukemias (70,71).  
 Rituximab is a chimeric mouse/human antibody against CD20 developed in 1991 at IDEC 
pharmaceuticals (73). It was approved to treat non-Hodgkin’s lymphoma in 1997 becoming the first monoclonal 
antibody approved for the treatment of cancer. It has since gone on to be approved for use against other 
lymphomas and leukemias, as well as autoimmune diseases such as rheumatoid arthritis. Rituximab is quite 
successful as an anti-cancer agent, showing promise as a single agent but true clinical value in combination with 
chemotherapy (74). Rituximab marks CD20 positive cells for destruction by natural killer cells (NK), 
neutrophils and macrophages, thereby selectively targeting malignant B-Cells for antibody-dependent cellular 
cytotoxicity (ADCC) (74,75). Rituximab triggers ADCC by permanently attaching to CD20 on the surface of B-
cells. The CD20 bound rituximab recruits the innate effector cells responsible for ADCC through an interaction 
of the Fc region of rituximab and the Fc gamma receptor (FcγR, CD16) on NK cells (76,77). Additionally, 
rituximab can deplete B-cells via apoptotic upregulation and complement-mediated cytotoxicity (CMC, CDC). 
Apoptosis is triggered by rituximab by the reorganization of CD20 into lipid rafts and induces changes to p38, 
NF-κB/bcl-2, ERK, and AKT (78). CMC in response to rituximab is linked to binding of the serum protein C1q 
to the Fc portion of the antibody thereby leading to cell lysis(78).  
 Rituximab, while highly effective in many patients, is certainly subject to therapeutic resistance. It is 
estimated that 30-60% of patients may show resistance to rituximab (79). As there are several mechanisms of 
rituximab cytotoxicity, there are likewise many means by which resistance may develop. For example, CMC in 
tumor cells may be blocked through the differential expression of membrane complement-regulatory proteins 
(mCRP). These proteins, such as CD46, CD55 and CD59, inhibit the complement cascade or membrane attack 
complex that is responsible for cell lysis in response to CMC (79,80). Also, as CMC is dependent on the 
interaction of rituximab with C1q, a depletion of this effector may lead to resistance to rituximab mediated 
cytotoxicity (79). The destruction of rituximab bound B-cells by immune effector cells is dependent on two 
variables: the binding of rituximab to FcγR, and the congregation of the bound CD20 into lipid rafts (77–79). 
Thus, decreases in the affinity of FcγR to rituximab or low numbers of NK cells with FcγR can diminish the 
efficacy of the treatment (78,79). Similarly, a lack of rituximab-CD20 polarization can inhibit ADCC (75). 
Additionally, resistance to the apoptotic effects of rituximab may be linked to decreases in pro-apoptotic 
signaling and upregulation of anti-apoptotic signaling. Overexpression of the MAP Kinase or PI3 Kinase 
pathways, as well as NF-κB hyperphosphorylation can all contribute to an attenuation of the pro-apoptotic 
nature of rituximab (78,81). While it would seem that the most likely mechanism for resistance would be 
changes to CD20 expression or affinity to rituximab, evidence for this is lacking (79).  
 CD20 remains a promising target for therapy in leukemias and lymphomas and as such there are several 
anti-CD20 monoclonal antibodies approved or in various stages of development. These include ocrelizumab, 
ofatumumab and others. These compounds are mechanistically similar to rituximab, but also likely share 
resistance mechanisms akin to rituximab. 
BRCA and PARP Inhibitors 
 The tumor suppressor genes BRCA1and BRCA2 are well-known for their association with hereditary 
breast and ovarian cancers. Carriers of BRCA1 and BRCA2 mutations have up to an 80% lifetime risk of 
developing breast cancer (82). These patients also have up to a 55% chance of developing ovarian cancer (82). 
The BRCA1 and BRCA2 genes are expressed in breast, ovarian and other tissues where they function to repair 
damaged DNA. Specifically, BRCA1 and BRCA2 act as part of a complex of proteins, most notably interacting 
with the recombinase RAD1, to repair double-strand breaks through homologous recombination (HR) and 
stabilization of stalled DNA synthesis (83–86). Cells defective in BRCA1 or BRCA2 demonstrate increased 
mutational rates due to the breakdown of DNA repair and thus are likely to become tumorigenic. 
 Poly(ADP-ribose) polymerases (PARPs), are a family of proteins whose primary function is to locate 
and repair single strand DNA breaks (SSB). PARPs, and in particular PARP1, bind to both single-strand and 
double-strand breaks and initiate DNA repair (87–89). PARP1 can also reactivate stalled replication forks (90). 
In cases where BRCA1 or BRCA2 function is compromised, PARPs play an important role in the cellular 
response to this loss of function. In addition to repairing SSBs and restarting stalled forks, in the absence of 
BRCA1/BRCA2 it is believed that PARPs can serve a further role in DSB repair (91,92). Therefore, in patients 
with defective BRCA homologous recombination mediated DNA repair, PARPs can be key proteins in 
regulating the amount of DNA damage accumulated within cancer cells. 
 The interplay of BRCA1/2 and PARPs in DNA repair, offers a unique target for clinical treatment. 
PARP inhibitors were first developed after the observation that PARP1 is activated by radiation and DNA-
methylating agents (89). It was thought that combining inhibition of PARPs with radiation, or DNA damaging 
agents may increase the efficacy of these more traditional cancer treatments. PARP inhibitors are effective anti-
cancer treatments, not only in combination with DNA damaging agents, but also as single agents in cells 
defective in HR. Cells lacking HR, due to defective BRCA1, BRCA2 or other repair proteins such as PALB2 
have proven to be excellent targets for PARP inhibition. In these cells, loss of PARP activity will increase the 
number of SSB, eventually leading to DSB when replication forks become stalled (93). The vast increase in 
damaged DNA in cells lacking both HR and PARP activity initiates a synthetic lethal effect (91). Additionally, 
it is thought that PARP inhibitors “trap” PARP proteins at the site of DNA damage and that this PARP 
“trapping” is also toxic to the cell (94). Both modes of action for PARP inhibitors are selective only for 
cancerous cells that lack HR and not for the surrounding normal cells with functional DNA repair. Many PARP 
inhibitors have been developed including olaparib, veliparib, rucaparib, and MK4827. 
 Mechanisms of PARP inhibitor resistance are just beginning to be understood. It has been found that 
isoforms of BRCA2 can arise in culture that restore some HR function to cancer cells harboring BRCA2 
mutations, allowing these cells to bypass the synthetic lethality of PARP inhibition (95,96). It is likely that such 
a mechanism of resistance could also be discovered in BRCA1 mutant cells. It is also possible that other 
methods of acquired or innate resistance to PARP inhibitors may arise, such as mutations in the active site of 
PARP1 that decreases drug affinity, changes in PARP expression or a decreased dependence on substrate for 
activity. In fact, many BRCA1 defective cancers have low or no PARP1 expression and resistant or refractory 
cancers often show decreased PARP activity relative to cancers that show high PARP inhibitor sensitivity (97). 
PARP inhibitor resistance can also arise from differential expression of other redundant DNA repair pathways. 
For example, it has been shown that some BRCA1 deficient breast cancers lose 53BP1 expression, a change 
that can lead to restoration of HR repair and PARP inhibitor resistance (98,99). Variability in clinical response 
to PARP inhibition has also been linked to the potency and specificity of the drugs being used, as greater than 
90% inhibition of PARP activity may be needed to significantly affect DNA repair (89). Nonetheless, PARP 
inhibitors either as single agents or in combination with DNA damaging agents continue to demonstrate results 
in many selected patients enrolled in clinical trials. 
HER2  
 HER2 (ErbB2) expression is amplified and the protein overexpressed in approximately 15-20% of breast 
cancers (100).  These “HER2 positive” cancers have traditionally been associated with aggressive disease and 
poor patient outcome. HER2 is a transmembrane receptor tyrosine kinase belonging to the ErbB/HER family. 
This family includes EGFR (HER1/ErbB1), and HER 2, 3 and 4. While each member of the family shares 
common tyrosine kinase domain motifs, they each contain unique ligand binding domains (101). HER2 is 
activated by autophosphorylation upon homo- and heterodimerization, and can dimerize with other members of 
the ErbB family. In fact, HER2 has been shown to be the preferred binding partner of the other ErbB receptors 
(102). Overexpression of HER2 alone is often adequate to trigger receptor phosphorylation and activation even 
in the absence of ligand. HER2 activates several proliferative pathways upon phosphorylation, including the 
MAP Kinase and PI3 Kinase pathways. Overexpression of HER2 leads to upregulation of these pathways and a 
proliferative and anti-apoptotic effect on cells.  
 The overexpression of HER2 in breast cancers (and now other cancers such as stomach cancers), has 
made it a strong candidate for targeted therapies. HER2 overexpression is present largely in cancer cells, but not 
in surrounding normal cells. Targeting HER2 would then limit toxicity exclusively to cancer cells in theory. In 
1998, the FDA approved trastuzumab (Herceptin) as the first targeted treatment against HER2 positive breast 
cancers. Trastuzumab is a monoclonal antibody specific to the juxtamembrane domain of HER2 and results in a 
downregulation of the protein (103–105). Trastuzumab also has other proposed anti-proliferative effects such as 
inhibiting transcription and decreasing the levels of a constitutively active truncated form of HER2 (p95-HER2) 
(104,106). Also, similar to the method of action for rituximab, trastuzumab can trigger antibody dependent 
cellular toxicity (ADCC) through an interaction between the antibody and Fc receptors on immune cells (77).  
 Trastuzumab is administered to patients with cancers overexpressing HER2 as a single agent or in 
combination with chemotherapy, such as paclitaxel. Combination therapies using trastuzumab have shown to 
greatly improve response rates, median survival and disease free survival (107,108). Like all targeted therapies, 
the successes of trastuzumab are balanced by occurrences of innate or acquired resistance. There are three 
proposed pathways of trastuzumab resistance, each inherently linked to the nature of HER2. These mechanisms 
of resistance include HER2-independent activation of the PI3 Kinase pathway, upregulation of the other HER 
family member receptors, and increased production of p95-HER2 (109,110).  
One of the primary signaling pathways activated by ErbB receptors is the PI3 Kinase pathway. PI3K is 
composed of two subunits, the p85 regulatory subunit and the p110 catalytic component. These subunits interact 
with activated HER2, thus beginning a signaling cascade, which ultimately results in cell proliferation, growth, 
invasion and other cancerous phenotypes. In many cancers, PI3K or downstream targets, such as AKT and 
MAPK can become constitutively activated independent of the signaling dependence from HER2 activation 
(111–113). For example, mutations that lead to loss of PTEN function, or activation of the PIK3CA gene 
(PIK3CA encodes for p110α) are frequent in breast cancer (111).  In these cases, targeting HER2 
overexpression with trastuzumab potentially lessens its anti-proliferative effects, as these cancers can grow 
without HER2 activation and have in preclinical models been associated with resistance (114)(115).  
The nature of HER2 as a family member of receptor tyrosine kinases, inherently allows for cells with 
inhibited HER2 to find alternative pathways for proliferation.  Redundancy in the downstream signaling 
pathways of HER2, HER3, EGFR and IGF-1R indicates that loss of signal from one of these receptors alone 
may not be enough to impede MAPK and PI3K activation (116). As example, the HER2-HER3 heterodimer has 
been shown to be an essential interaction for HER2 dependent tumorigenesis (117). HER2 independent 
activation of HER3 or EGFR may lead to HER2 positive cancers that lack sensitivity to trastuzumab (117–119). 
In addition to redundancy within the members of the ErbB family of membrane receptors, IGF-1R has been 
demonstrated to activate PI3K through crosstalk with HER2 (120). It has been purposed that IGF-1R 
stimulation in certain cancer cells may be a source of trastuzumab resistance, and inhibition of IGF-1R can 
restore trastuzumab sensitivity (121). 
As previously mentioned, a truncated form of HER2, p95-HER2, can also be expressed in cells. This 
protein lacks the amino terminus of HER2 and therefore lacks the binding site for trastuzumab. Moreover, p95-
HER2 is constitutively active, and downstream targets become phosphorylated independent of ligand 
interaction. While trastuzumab treatment has been shown to decrease p95-HER2 expression, 30% of HER2 
positive tumors overexpress p95-HER2 (104,122). Thus it has been proposed that cancers with increased levels 
of p95-HER2 are relatively resistant to trastuzumab’s anti-neoplastic effects.  
Targeting HER2 with trastuzumab is now standard treatment for HER2 amplified/overexpressing breast 
cancers and as mentioned, some GI cancers as well. On the heels of this success, alternative treatments against 
HER2 have been developed. Pertuzumab is another monoclonal antibody directed against HER2 that was 
approved for use in 2012. However, pertuzumab interacts with the dimerization domain of HER2, blocking the 
homo- and heterodimerization of HER2 (110). This antibody shows promise over trastuzumab, in that it can 
inhibit not only HER2 stimulated growth, but also the dimerization dependent activation of the other members 
of the ErbB family, specifically HER3 (123,124)(125). Also, unlike trastuzumab, pertuzumab may be able to 
inhibit p95-HER2 mediated growth (126). Clinical data indicates that trastuzumab and pertuzumab are 
complementary and can be highly effective when used in combination (127). These benefits, along with 
retaining the ability to stimulate ADCC, make pertuzumab an attractive option for HER2-positive cancers. 
There have also been studies to increase the effectiveness of trastuzumab, leading to the development of 
TDM-1, which was approved by the FDA in 2013. TDM-1 is a conjugate of trastuzumab with DM1 (derivative 
of maytansine 1), a microtubule inhibitor. This antibody-drug conjugate (ADC) is designed to combine the anti-
proliferative effects of trastuzumab with targeted delivery of the cytotoxic compound DM-1 directly to HER2 
overexpressing cells. TDM-1 shows promise in attacking cells that may be resistant to trastuzumab, and 
demonstrates retention of trastuzumab’s other anti-neoplastic functions such as PI3K signal inhibition, 
decreases in p95-HER2 mediated signaling and ADCC (128,129). 
In addition to these antibody-based approaches for targeting HER2, small molecules that inhibit the 
kinase activity of HER2 have been developed, most notably lapatinib. Lapatanib, approved in 2007, is a small 
molecule inhibitor of EGFR and HER2, which competitively binds to the ATP-binding domain thus blocking 
autophosphorylation. Lapatinib is indicated for HER2 positive breast cancers that have progressed with standard 
trastuzumab containing regimens. Due to the specificity for the ATP-binding pocket, lapatinib may have distinct 
mechanisms of resistance compared to trastuzumab. Nonetheless, lapatinib resistance can still occur via several 
mechanisms. Activating mutations of the PI3 Kinase pathway may also contribute to lapatinib resistance, as can 
loss of PTEN function (130). A mutation in the ATP binding pocket of HER2 (L755S) has also been reported to 
confer lapatinib resistance in vitro (131). It has also been purposed that activation of IGF-1R, ER or other 
receptor tyrosine kinases (such as AXL) may lead to tumors resistant to lapatinib treatment (132,133). 
EGFR inhibitors 
 EGFR (HER1, ErbB1) is overexpressed and/or mutated in many cancers including lung and colon 
cancers. EGFR is a receptor tyrosine kinase activated by binding with epidermal growth factor (EGF), 
transforming growth factor α (TGFα), and other ligands (116). Activation of EGFR initiates several cell 
proliferating signal transduction cascades including the MAP Kinase, PI3 Kinase, JNK and STAT pathways 
(116). The tendency for EGFR to be upregulated or mutated in nearly 30% of epithelial cancers, demonstrates 
its high therapeutic potential for targeted therapy. To date, several compounds have been developed for 
treatment against EGFR-activated cancers including small molecule inhibitors such as gefitinib, erlotinib and 
antibody based therapies such as cetuximab. 
 Gefitinib (Iressa) and erlotinib (Tarceva) are small molecule inhibitors of EGFR which were approved 
for the treatment of EGFR positive lung cancer in the past decade. Both compounds reversibly inhibit EGFR 
kinase activity by competitively binding the ATP binding site (134,135). It was soon discovered that these drugs 
not only block EGFR activation, but that the best predictors of response were specific EGFR activating 
mutations (136). These sensitizing mutations were found in the tyrosine kinase domain, either in deletions 
within exon 19 between codons 746 and 759, or in exon 21 at L858R (136,137). However, while these 
mutations can increase the sensitivity of tumor cells to gefitinib or erlotinib, subsequent analyses have identified 
mutations that can confer drug resistance. The most clinically relevant resistance mutation in EGFR is in exon 
20 at T790M (138,139). This mutation is thought to block the binding of inhibitors to the ATP binding site, thus 
leading to the constitutive activation of EGFR (140). This mechanism of resistance may be overcome with the 
introduction of irreversible EGFR inhibitors (141). Interestingly, another EGFR mutation within exon 19 at 
D761Y has been linked to gefitinib and erlotinib resistance in tumors that contain the L858R mutation 
(142,143). As in the case with many kinase inhibitors, resistance can also occur through activation of 
downstream pathways, such as PI3K (144). Likewise, activation of other receptor tyrosine kinases such as 
MET, IGFR-1, PDGF and additional ErbB family members has been linked to acquired gefitinib and erlotinib 
resistance (125,144).  
 Cetuximab (Erbitux) and panitumumab (Vectibix) are monoclonal antibodies against EGFR that are 
clinically used for the treatment of colorectal and other cancers. These antibodies bind to the extracellular 
domain of EGFR and are thought to change the conformation of the dimerization domain thereby 
simultaneously blocking ligand binding and preventing receptor dimerization (145). The resultant inhibition of 
EGFR phosphorylation combined with several other mechanisms of action contribute towards cetuximab’s and 
panitumumab’s efficacy against EGFR positive tumors (146). 
 One well classified determinant of EGFR antibody therapeutic sensitivity is the mutational status of 
KRAS. Constitutive activation of the MAP Kinase signaling pathway downstream of EGFR bypasses the 
effectiveness of cetuximab and panitumumab. In fact, patients with KRAS activating mutations have a poorer 
predicted outcome than those with wild type KRAS (147–149). As a result, KRAS mutational status is screened 
for prior to the administration of these therapeutic antibodies. More recently, two independent groups have 
demonstrated the appearance of KRAS mutations within sites of progressive disease in metastatic colon cancer 
patients treated with anti-EGFR antibody therapies (150,151).  Mutations in BRAF, a serine-threonine kinase in 
the MAP Kinase pathway immediately downstream of KRAS, have also been linked to EGFR antibody 
resistance.  Specifically, the V600E activating mutation is strongly associated to poor response to EGFR 
antibody therapy (152). Activating mutations of other downstream effectors of EGFR have also been linked to 
antibody resistance.  For example, constitutive activation of AKT or PI3K, or loss of PTEN can diminish 
responses to EGFR antibody therapies (146,153). Finally, MET amplification has also been recently shown to 
be associated with acquired resistance to EGFR antibody therapies in colon cancers that are wild type for KRAS 
(154).  
 There are other documented mechanisms of EGFR antibody resistance. One method has been the 
production of VEGF leading to EGFR antibody resistance. The increased vascularization and activation of 
growth pathways by VEGFR is thought to bypass much of the anti-migratory and anti-proliferative effects of 
EGFR inhibition (155,156). Localization of EGFR to the nucleus may also be a contributor to sensitivity versus 
resistance (146). As in EGFR small molecule inhibitor resistance, changes in expression levels of the receptor 
tyrosine kinase family members HER2, HER3 and IGFR1 can also impart resistance to EGFR antibody 
therapies [143,145].  
BRAF 
 The cytoplasmic serine/threonine protein kinase BRAF is a critical member of the MAP Kinase signal 
transduction pathway. Oncogenic mutations in both RAS and BRAF have been thoroughly described, with 
activating RAS mutations reported in ~15% of cancers, and BRAF mutations described in several cancer types 
including melanoma, colorectal, ovarian and papillary thyroid carcinomas (37). Nearly 66% percent of 
melanomas harbor BRAF mutations and of those, 80% of the mutations are a single base pair substitution in the 
kinase domain yielding V600E (157). The extremely high frequency of V600E mutations in malignant 
melanoma along with its role in resistance to other “upstream” therapies demonstrates high clinical potential as 
a target for treatment and predictor of response to targeted therapies. Currently, there are FDA approved 
therapies that target the V600E and other V600 mutations in clinical use: vemurafenib and dabrafenib. 
Vemurafenib, approved for clinical use in 2011, is a kinase inhibitor that selectively targets cells harboring 
V600E mutations, but has little effect on wild-type BRAF cells (158). When interacting with mutated BRAF, 
vemurafenib locks onto the ATP-binding site and will downregulate ERK signaling, inducing cell cycle arrest 
and activating apoptosis (158,159). Treatment with vemurafenib can be highly effective and many patients 
demonstrate significant (up to 80%) clinical response (160). More recently, dabrafenib in combination with the 
MEK inhibitor trametinib has also been shown as effective therapy for metastatic melanomas that harbor BRAF 
V600 mutations (161).   
There are several described mechanisms of vemurafenib resistance, which eventually occurs in virtually 
all metastatic patients. Upregulation of PDGFRβ has been recognized as a mode of acquired resistance in a 
subset of melanomas (162). Alternatively, the up-regulation or mutation of oncogenic NRAS can also contribute 
to loss of vemurafenib sensitivity (162), further substantiated by a recent clinical report demonstrating 
mutations in NRAS and MEK being associated with vemurafenib resistant melanomas (163). The tumor micro-
environment can also play a role in BRAF inhibitor resistance. Secretion of hepatocyte growth factor can 
stimulate MET leading to activation of the PI3 Kinase and MAP Kinase pathways independent of RAF 
inhibition (164). In addition, early attempts using vemurafenib in BRAF V600E mutant colon cancers did not 
demonstrate any appreciable response.  Although mutant BRAF has been shown to predict for resistance against 
EGFR mediated therapies as mentioned above, recent work suggests an even more complex interplay.  It 
appears that mutant BRAF suppression leads to feedback activation of EGFR in colon cancer cells resulting in  
vemurafenib resistance, suggesting the need to simultaneously target both proteins (165). Interestingly, it has 
been shown that vemurafenib treatment can paradoxically stimulate MAP Kinase signaling and may promote 
tumorigenesis in cells with wild type RAF (159). 
EML4-ALK 
 Nearly 5% of non-small cell lung cancer cases are estimated to harbor a somatic translocation between 
echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) (166). The 
resultant EML4-ALK protein and others produced from ALK translocations, are hyperactive versions of the 
ALK receptor tyrosine kinase (167,168). Inspired by the success of BCR-ABL targeting with imatinib, a 
selective inhibitor of ALK was quickly developed. Crizotinib is a competitive inhibitor of the kinase activity 
that interacts with the ATP binding domain of ALK, ROS1 and MET (169). Crizotinib inhibits cell proliferation 
and angiogenesis, initiates cell arrest and can induce apoptosis (170). With a response rate of ~60%, acquired 
and innate resistance to crizotinib has also been documented (168).  
Several mutations in ALK have been linked to crizotinib resistance. The most well documented of these 
is L1196M which impedes inhibitor binding to the active site (171). Other resistance mutations have been 
identified in the kinase domain, as well as mutations that increase ATP affinity thus decreasing the effectiveness 
of competitive inhibition (168). Copy number increases in ALK can also decrease the efficacy of competitive 
inhibition by crizotinib (172). Alternatively, activation of other proliferative mechanisms can decrease tumor 
sensitivity to crizotinib. Specifically, upregulation of EGFR, HER2 or HER3, constitutive activating mutations 
in EGFR (L858R and S7681) as well as KRAS G12C and G12V mutations have been reported to be associated 
with a decrease in ALK inhibitor sensitivity (168,173).  
Other Targeted Therapies and Conclusions 
 The past success and future potential of targeted therapies for cancer are evident, and many new drugs 
are currently in development. An obvious candidate for targeted therapy is PI3K, or specifically the p110α 
component encoded by the PIK3CA gene. PIK3CA is the second most commonly mutated gene in the cancer 
genome with a relatively high frequency found in lung, breast, brain, gastric, colon and other cancers (111,174). 
A high frequency of three “hotspot” PIK3CA mutations are found in two coding regions of the gene:  the kinase 
domain in exon 9 (E542K, E545K) and the helical domain in exon 20 (H1047R) (175). These are not only 
common oncogenic mutations, but as described above, they also have been closely linked to resistance with 
receptor tyrosine kinase antibody targeted therapies. As such, there is currently much interest in developing 
PI3K inhibitors for cancer therapy (176–178). However, due to numerous classes and isoforms of PI3Ks, the 
isolation of compounds specific for activated p110α has proved challenging, and early generation PI3K 
inhibitors had predicted side effects due to off target effects of inhibiting other PI3K isoforms. Thus, the ability 
of using mutant PIK3CA as a predictor of response to these early compounds has not been uniformly observed 
and as a consequence knowledge of genetic effectors of resistance (and sensitivity) is lacking. 
Other targets within the PI3 Kinase and MAP Kinase pathways are currently being pursued. AKT 
(protein kinase B) is a serine/threonine kinase in the PI3K/AKT/mTOR pathway that is often mutated and/or 
activated in human cancers (179). The three isoforms of AKT play key roles in activation of the cell cycle, 
angiogenesis, cell metabolism and cell survival (180). Similar to PIK3CA, AKT is a heavily pursued target for 
targeted therapies with numerous inhibitors at various stages of clinical development.  MEK is another kinase 
downstream of RAS-RAF signaling within the MAP Kinase pathway. Targeting of this kinase has resulted in 
the development of several small molecule inhibitors including trametinib as mentioned above, and selumetinib 
(AZD6244).  Based upon laboratory data and early clinical trials, there is a high level of optimism that targeted 
therapies against the above described kinases either as single agents or in combination will lead to new 
approved therapies over the next few years for a variety of human cancers.  
An emerging area for targeted cancer therapies is the Hedgehog pathway. Hedgehog (Hh) signaling is 
key to embryogenesis, regulating the patterning and polarity of developing cells. Hh expression is silenced in 
mature cells, but can be activated by overexpression of ligand in certain cancer cells (181). Aberrant Hh 
signaling has been demonstrated in lung, pancreas, colorectal, and prostate cancers, as well as melanomas, 
lymphomas, multiple myelomas and glioblastomas (181). This activation is thought to support cell proliferation, 
angiogenesis, cell survival, cell migration and metastasis (181–183). Hh signaling is also a major component in 
the control, proliferation and differentiation of cancer stems cells (183). Thus, members of this pathway are 
strong candidates for anti-cancer targeted therapies. As example, vismodegib (GDC-0449), a small molecule 
inhibitor of the Hh pathway, has demonstrated significant activity in basal cell carcinoma, leading to its recent 
approval (184). Similar to many small molecule inhibitors, vismodegib is initially remarkably effective, but 
prolonged treatment often leads to acquired resistance. Resistance to this drug has been linked to mutation of 
the ligand binding pocket of the target receptor (SMO), gene duplications and overexpression of cyclin D or 
Gli2, and activation of the PI3 Kinase pathway (185–187). 
Over the past two decades, targeted therapies for cancer have made a significant impact on the morbidity 
and mortality inflicted by this group of diseases.  These historic and recent examples demonstrate that the future 
of cancer medicine lies in the pursuit of better patient and tumor-specific therapies, and that genetic knowledge 
of cancer genomes can help guide these efforts. Much attention has been given to the clinical development of 
targeted therapies in the form of antibodies or small molecule inhibitors. The relative specificity of these drugs, 
combined with lower toxicity when compared to radiation and chemotherapy make them attractive for both 
clinicians and patients. Currently most efforts have been focused on the inhibition of kinase activity, and most 
drugs/compounds to date have similar mechanisms of action. Newer research emerging from academic labs and 
industry partners are now focused on novel methods and companion diagnostics to best match patients with the 
optimal targeted therapies.  Importantly, the identification and validation of new types of targets remains as an 
important and high priority. Despite the past successes, drug resistance continues to be a common problem 
among targeted therapies limiting their use. As one might have predicted, the mechanisms of drug resistance are 
as complex and diverse as each individual’s cancer genome.  Activation of redundant pathways as well as 
selection for genetic alterations such as mutations and amplifications all contribute to the phenomenon of 
resistance to targeted therapies. Future research will therefore emphasize the use of multiple therapies that block 
cancer cell signaling across many pathways, as well as nodal points within each of these pathways. How this 
can be accomplished while maintaining a tolerable toxicity profile presents a challenge for future drug 
development. Further complicating this problem, the genetic instability of cancer cells leads to tumor 
heterogeneity which predicts a Darwinian selection process in metastatic disease favoring the emergence of 
drug resistant populations. This calls for not only the continued development of targeted therapies, but a better 
understanding of the moving landscape of a patient’s cancer genome. Current and future technological 
breakthroughs in DNA sequencing and expression profiling may allow scientists and clinicians to better 
understand their patient’s individual disease at a given time point allowing for tailored treatment regimen to 
prevent or combat drug resistance. Clearly, great strides have been made in the assessment and treatment of 
cancer, yet much work remains in finding true cures for this disease. 
Acknowledgements 
B.G.B. is supported by a DOD BCRP Postdoctoral Fellowship Award (BC100972). B.H.P. receives support 
from the Flight Attendant Medical Research Institute (FAMRI), The Breast Cancer Research Foundation, The 
Avon Foundation, the Commonwealth Foundation, JHU Singapore/Santa Fe Foundation, the Safeway 
Foundation and the Eddie and Sandy Garcia Foundation. 
 
Footnotes 
We apologize to our colleagues whose important work could not be cited due to space constraints.  
 
Author contributions 
B.G.B., A.B. and B.H.P. wrote and revised the manuscript. 
 
 
References 
1.  Jensen E V, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res. 
1962;18(4):387.  
2.  Robinson-Rechavi M. The nuclear receptor superfamily. Journal of Cell Science. 2003 Feb;116(4):585–
6.  
3.  Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. British 
medical journal. 1973 Jan;1(5844):13–4.  
4.  KIANG DT. Tamoxifen (Antiestrogen) Therapy in Advanced Breast Cancer. Annals of Internal 
Medicine. American College of Physicians; 1977 Dec;87(6):687.  
5.  Abukhdeir AM, Vitolo MI, Argani P, et al. Tamoxifen-stimulated growth of breast cancer due to p21 
loss. Proc Natl Acad Sci U S A. 2008;105(1):288–93.  
6.  Jones SE. Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor. Seminars 
in oncology. 2003 Oct;30(5 Suppl 16):14–20.  
7.  Evaluation of the molecular mechanisms behind fulvestrant resistant breast cancer -- Kirkegaard et al. 72 
(1024): P6-04-18 -- Cancer Research [Internet]. [cited 2013 May 10].  
8.  Miller WR, Larionov AA. Understanding the mechanisms of aromatase inhibitor resistance. Breast 
cancer research : BCR. 2012 Jan;14(1):201.  
9.  Lonning P, Eikesdal HP. Aromatase inhibition 2013: clinical state of the art and questions that remain to 
be solved. Endocrine-related cancer. 2013 Apr;  
10.  Huggins C, Hodges C V. Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of 
Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. CA: A Cancer 
Journal for Clinicians. 1972 Jul;22(4):232–40.  
11.  Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 
92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate 
cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 
May;26(15):2497–504.  
12.  Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. BJU international. 
2012 Oct;110 Suppl:23–9.  
13.  Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus 
treated history of disease. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 1997 Aug;15(8):2928–38.  
14.  Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: 
effect of prior hormonal therapy. The Journal of urology. 1998 Jan;159(1):149–53.  
15.  Friedlander TW, Ryan CJ. Targeting the androgen receptor. The Urologic clinics of North America. 2012 
Nov;39(4):453–64.  
16.  Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of 
advanced prostate cancer. Science (New York, NY). 2009 May;324(5928):787–90.  
17.  Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to 2nd 
generation anti-androgens enzalutamide and ARN-509. Cancer discovery. American Association for 
Cancer Research; 2013 Jun 18 [cited 2013 Aug 8];  
18.  Hara T, Miyazaki J, Araki H, et al. Novel Mutations of Androgen Receptor: A Possible Mechanism of 
Bicalutamide Withdrawal Syndrome. Cancer Res. 2003 Jan 1 [cited 2013 Aug 8];63(1):149–53.  
19.  Larson RA, Kondo K, Vardiman JW, et al. Evidence for a 15;17 translocation in every patient with acute 
promyelocytic leukemia. The American journal of medicine. 1984 May;76(5):827–41.  
20.  Tang X-H, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annual review of pathology. 2011 
Jan;6:345–64.  
21.  Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annual review of nutrition. 2004 
Jan;24:201–21.  
22.  Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic 
leukemia. Blood. 1988 Aug;72(2):567–72.  
23.  Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute 
promyelocytic leukemia. I. Clinical results. Blood. 1990 Nov;76(9):1704–9.  
24.  Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. Nature 
Publishing Group; 2001 Oct;20(49):7140–5.  
25.  Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, 
targeted anticancer drug. Nature reviews Drug discovery. 2002 Jul;1(7):493–502.  
26.  NOWELL P, HUNGERFORD D. MINUTE CHROMOSOME IN HUMAN CHRONIC 
GRANULOCYTIC LEUKEMIA. Science. 1960. p. 1497 – 1497.  
27.  Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia 
identified by quinacrine fluorescence and Giemsa staining. Nature. 1973 Jun;243(5405):290–3.  
28.  Waller CF. Imatinib mesylate. Recent results in cancer research Fortschritte der Krebsforschung Progrès 
dans les recherches sur le cancer. 2010 Jan;184:3–20.  
29.  Schindler T. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase. Science. 2000 
Sep;289(5486):1938–42.  
30.  Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). Journal of cellular 
and molecular medicine. 2010 Jan;14(1-2):42–50.  
31.  Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. 
Leukemia. Macmillan Publishers Limited; 2011 Jan;25(1):7–22.  
32.  Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. 
Current opinion in genetics & development. 2008 Feb;18(1):73–9.  
33.  Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by 
BCR-ABL gene mutation or amplification. Science (New York, NY). 2001 Aug;293(5531):876–80.  
34.  Griswold IJ, MacPartlin M, Bumm T, et al. Kinase domain mutants of Bcr-Abl exhibit altered 
transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. 
Molecular and cellular biology. 2006 Aug;26(16):6082–93.  
35.  Faivre S, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical 
development. Nature reviews Drug discovery. Nature Publishing Group; 2007 Sep;6(9):734–45.  
36.  Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor 
for treating cancer. Nature reviews Drug discovery. 2006 Oct;5(10):835–44.  
37.  Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by 
oncogenic mutations of B-RAF. Cell. 2004 Mar;116(6):855–67.  
38.  Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 
2009 Jan;69(2):223–40.  
39.  Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 
as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast 
cancer. Molecular cancer therapeutics. 2003 Oct;2(10):1011–21.  
40.  Barattè S, Sarati S, Frigerio E, et al. Quantitation of SU1 1248, an oral multi-target tyrosine kinase 
inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry 
following semi-automated liquid-liquid extraction. Journal of chromatography A. 2004 Jan;1024(1-
2):87–94.  
41.  Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its 
therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). 
Therapeutics and clinical risk management. 2007 Jun;3(2):341–8.  
42.  Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase 
inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: 
determination of a pharmacokinetic/pharmacodynamic relationship. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 2003 Jan;9(1):327–37.  
43.  O’Farrell A-M, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition 
of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clinical cancer research : an 
official journal of the American Association for Cancer Research. 2003 Nov;9(15):5465–76.  
44.  Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with 
advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 
2006 Oct;368(9544):1329–38.  
45.  Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature reviews Cancer. Nature 
Publishing Group; 2008 Aug;8(8):592–603.  
46.  Gotink KJ, Broxterman HJ, Labots M, et al. Lysosomal sequestration of sunitinib: a novel mechanism of 
drug resistance. Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2011 Dec;17(23):7337–46.  
47.  Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in 
yeast. Science (New York, NY). 1991 Aug;253(5022):905–9.  
48.  Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling 
symphony. The Journal of biological chemistry. 2010 May;285(19):14071–7.  
49.  Brown EJ, Albers MW, Bum Shin T, et al. A mammalian protein targeted by G1-arresting rapamycin–
receptor complex. Nature. 1994 Jun;369(6483):756–8.  
50.  Huang S, Bjornsti M-A, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer 
biology & therapy. 2(3):222–32.  
51.  Dobashi Y, Watanabe Y, Miwa C, et al. Mammalian target of rapamycin: a central node of complex 
signaling cascades. International journal of clinical and experimental pathology. 2011 Jun;4(5):476–95.  
52.  Bjornsti M-A, Houghton PJ. The TOR pathway: a target for cancer therapy. Nature reviews Cancer. 2004 
May;4(5):335–48.  
53.  Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nature 
reviews Drug discovery. 2006 Aug;5(8):671–88.  
54.  Yuan R, Kay A, Berg WJ, et al. Targeting tumorigenesis: development and use of mTOR inhibitors in 
cancer therapy. Journal of hematology & oncology. 2009 Jan;2(1):45.  
55.  Dumont FJ, Staruch MJ, Grammer T, et al. Dominant mutations confer resistance to the 
immunosuppressant, rapamycin, in variants of a T cell lymphoma. Cellular immunology. 1995 
Jun;163(1):70–9.  
56.  Fruman DA, Wood MA, Gjertson CK, et al. FK506 binding protein 12 mediates sensitivity to both 
FK506 and rapamycin in murine mast cells. European journal of immunology. 1995 Mar;25(2):563–71.  
57.  Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with 
FKBP12-rapamycin. The Journal of biological chemistry. 1995 Nov;270(46):27531–7.  
58.  Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation 
through a PI3K-dependent feedback loop in human cancer. The Journal of clinical investigation. 2008 
Sep;118(9):3065–74.  
59.  Shi Y, Yan H, Frost P, et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in 
multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor 
substrate-1/phosphatidylinositol 3-kinase cascade. Molecular cancer therapeutics. 2005 Oct;4(10):1533–
40.  
60.  Tan J, Lee PL, Li Z, et al. B55β-associated PP2A complex controls PDK1-directed myc signaling and 
modulates rapamycin sensitivity in colorectal cancer. Cancer cell. 2010 Nov;18(5):459–71.  
61.  Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-
mTOR complex. Science (New York, NY). 2005 Feb;307(5712):1098–101.  
62.  Dilling MB, Germain GS, Dudkin L, et al. 4E-binding proteins, the suppressors of eukaryotic initiation 
factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. The Journal of 
biological chemistry. 2002 Apr;277(16):13907–17.  
63.  Graff JR, Konicek BW, Carter JH, et al. Targeting the eukaryotic translation initiation factor 4E for 
cancer therapy. Cancer research. 2008 Feb;68(3):631–4.  
64.  Mahalingam D, Medina EC, Esquivel JA, et al. Vorinostat enhances the activity of temsirolimus in renal 
cell carcinoma through suppression of survivin levels. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2010 Jan;16(1):141–53.  
65.  Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate 
intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature 
medicine. 2004 Jun;10(6):594–601.  
66.  Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor 
growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature medicine. 2002 
Mar;8(2):128–35.  
67.  Chapuis N, Tamburini J, Green AS, et al. Perspectives on inhibiting mTOR as a future treatment strategy 
for hematological malignancies. Leukemia. Macmillan Publishers Limited; 2010 Oct;24(10):1686–99.  
68.  Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, 
and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. The Journal 
of clinical investigation. 2008 Sep;118(9):3038–50.  
69.  Ishibashi K, Suzuki M, Sasaki S, et al. Identification of a new multigene four-transmembrane family 
(MS4A) related to CD20, HTm4 and β subunit of the high-affinity IgE receptor. Gene. 2001 
Feb;264(1):87–93.  
70.  Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen identifying lymphoid malignancies of B 
cell origin. The Journal of clinical investigation. American Society for Clinical Investigation; 1981 
Jan;67(1):134–40.  
71.  Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology today. 
1994 Sep;15(9):450–4.  
72.  OETTGEN HC, BAYARD PJ, VAN EWIJK W, et al. Further Biochemical Studies of the Human B-Cell 
Differentiation Antigens B1 and B2. Hybridoma. 1983 Jan;2(1):17–28.  
73.  Grillo-López AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first 
monoclonal antibody approved for the treatment of lymphoma. Seminars in oncology. 1999 Oct;26(5 
Suppl 14):66–73.  
74.  Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. 
Molecular immunology. 2007 Sep;44(16):3823–37.  
75.  Rudnicka D, Oszmiana A, Finch DK, et al. Rituximab causes a polarisation of B cells which augments its 
therapeutic function in NK cell-mediated antibody-dependent cellular cytotoxicity. Blood. 2013 
Apr;blood–2013–02–482570–.  
76.  Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal 
antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002 Feb;99(3):754–8.  
77.  Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against 
tumor targets. Nature medicine. 2000 Apr;6(4):443–6.  
78.  Weiner GJ. Rituximab: mechanism of action. Seminars in hematology. 2010 Apr;47(2):115–23.  
79.  Rezvani AR, Maloney DG. Rituximab resistance. Best practice & research Clinical haematology. 2011 
Jun;24(2):203–16.  
80.  Takei K, Yamazaki T, Sawada U, et al. Analysis of changes in CD20, CD55, and CD59 expression on 
established rituximab-resistant B-lymphoma cell lines. Leukemia research. 2006 May;30(5):625–31.  
81.  Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered 
cell signaling and cross-resistance to chemotherapy. Cancer research. 2007 Mar;67(3):1270–81.  
82.  Euhus DM, Robinson L. Genetic predisposition syndromes and their management. The Surgical clinics 
of North America. 2013 Apr;93(2):341–62.  
83.  PATEL K. Involvement of Brca2 in DNA Repair. Molecular Cell. 1998 Feb;1(3):347–57.  
84.  Moynahan ME, Pierce AJ, Jasin M. BRCA2 Is Required for Homology-Directed Repair of Chromosomal 
Breaks. Molecular Cell. 2001 Feb;7(2):263–72.  
85.  Moynahan ME, Chiu JW, Koller BH, et al. Brca1 Controls Homology-Directed DNA Repair. Molecular 
Cell. 1999 Oct;4(4):511–8.  
86.  Lomonosov M, Anand S, Sangrithi M, et al. Stabilization of stalled DNA replication forks by the BRCA2 
breast cancer susceptibility protein. Genes & development. 2003 Dec;17(24):3017–22.  
87.  Gradwohl G, Ménissier de Murcia JM, Molinete M, et al. The second zinc-finger domain of poly(ADP-
ribose) polymerase determines specificity for single-stranded breaks in DNA. Proceedings of the 
National Academy of Sciences of the United States of America. 1990 Apr;87(8):2990–4.  
88.  McGlynn P, Lloyd RG. Recombinational repair and restart of damaged replication forks. Nature reviews 
Molecular cell biology. 2002 Nov;3(11):859–70.  
89.  Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nature reviews Cancer. 
Nature Publishing Group; 2010 Apr;10(4):293–301.  
90.  Yang Y-G, Cortes U, Patnaik S, et al. Ablation of PARP-1 does not interfere with the repair of DNA 
double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene. 2004 
May;23(21):3872–82.  
91.  Saleh-Gohari N, Bryant HE, Schultz N, et al. Spontaneous homologous recombination is induced by 
collapsed replication forks that are caused by endogenous DNA single-strand breaks. Molecular and 
cellular biology. 2005 Aug;25(16):7158–69.  
92.  Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing 
radiation in mammalian cells: the molecular choreography. Mutation research. 751(2):158–246.  
93.  Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nature 
reviews Cancer. Nature Publishing Group; 2008 Mar;8(3):193–204.  
94.  Murai J, Huang SN, Das BB, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer 
research. 2012 Nov;72(21):5588–99.  
95.  Ashworth A. Drug resistance caused by reversion mutation. Cancer research. 2008 Dec;68(24):10021–3.  
96.  Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. 
Nature. 2008 Feb;451(7182):1111–5.  
97.  Domagala P, Huzarski T, Lubinski J, et al. PARP-1 expression in breast cancer including BRCA1-
associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. 
Breast cancer research and treatment. 2011 Jun;127(3):861–9.  
98.  Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with 
triple-negative and BRCA-mutated breast cancers. Nature structural & molecular biology. Nature 
Publishing Group; 2010 Jun;17(6):688–95.  
99.  Bunting SF, Callén E, Wong N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells 
by blocking resection of DNA breaks. Cell. 2010 Apr;141(2):243–54.  
100.  Sjögren S, Inganäs M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in 
primary breast cancer, alone and in combination with other prognostic markers. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 1998 Feb;16(2):462–9.  
101.  Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast 
and ovarian cancer. Science (New York, NY). 1989 May;244(4905):707–12.  
102.  Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB 
receptors, is a mediator of lateral signaling. The EMBO journal. 1997 Apr;16(7):1647–55.  
103.  Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 receptor by trastuzumab 
(herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in 
breast and ovarian cancer cell lines that overexpress erbB-2. Cancer research. 2001 Jun;61(12):4892–
900.  
104.  Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor 
monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. 
Cancer research. 2001 Jun;61(12):4744–9.  
105.  Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nature 
medicine. 2001 May;7(5):548–52.  
106.  Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by 
trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer cell. 2009 
May;15(5):429–40.  
107.  Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in 
HER2-positive breast cancer. The New England journal of medicine. 2005 Oct;353(16):1659–72.  
108.  Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-
positive breast cancer. The New England journal of medicine. 2005 Oct;353(16):1673–84.  
109.  Lim B, Cream L V, Harvey HA. Update on clinical trials: genetic targets in breast cancer. Advances in 
experimental medicine and biology. 2013 Jan;779:35–54.  
110.  Stopeck AT, Brown-Glaberman U, Wong HY, et al. The role of targeted therapy and biomarkers in 
breast cancer treatment. Clinical & experimental metastasis. 2012 Oct;29(7):807–19.  
111.  Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human 
breast cancers. Cancer biology & therapy. 2004 Aug;3(8):772–5.  
112.  Park BH, Davidson NE. PI3 kinase activation and response to Trastuzumab Therapy: what’s neu with 
herceptin resistance? Cancer cell. 2007 Oct;12(4):297–9.  
113.  Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Current 
cancer drug targets. 2008 Dec;8(8):733–40.  
114.  Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and 
loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117–27.  
115.  Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway 
as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395–402.  
116.  Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature reviews 
Cancer. 2005 May;5(5):341–54.  
117.  Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: 
implications for targeted therapy. Cancer research. 2008 Jul;68(14):5878–87.  
118.  Sergina N V, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the 
kinase-inactive HER3. Nature. 2007 Jan;445(7126):437–41.  
119.  Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to 
trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain 
dependent on the ErbB receptor network. Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2007 Aug;13(16):4909–19.  
120.  Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab 
(Herceptin). Journal of the National Cancer Institute. 2001 Dec;93(24):1852–7.  
121.  Nahta R, Yuan LXH, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor 
receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer 
research. 2005 Dec;65(23):11118–28.  
122.  Sáez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-
positive breast cancer. Clinical cancer research : an official journal of the American Association for 
Cancer Research. 2006 Jan;12(2):424–31.  
123.  Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-
pertuzumab complex. Cancer cell. 2004 Apr;5(4):317–28.  
124.  Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to 
produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer immunology, immunotherapy : 
CII. 2006 Jun;55(6):717–27.  
125.  Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung 
cancer by activating ERBB3 signaling. Science (New York, NY). 2007 May;316(5827):1039–43.  
126.  Recupero D, Daniele L, Marchiò C, et al. Spontaneous and pronase-induced HER2 truncation increases 
the trastuzumab binding capacity of breast cancer tissues and cell lines. The Journal of pathology. 2013 
Feb;229(3):390–9.  
127.  Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and 
pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer research. 
2009 Dec;69(24):9330–6.  
128.  Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-
DM1, an antibody-cytotoxic drug conjugate. Cancer research. 2008 Nov;68(22):9280–90.  
129.  Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of 
trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast cancer research 
and treatment. 2011 Jul;128(2):347–56.  
130.  Hurvitz SA, Hu Y, O’Brien N, et al. Current approaches and future directions in the treatment of HER2-
positive breast cancer. Cancer treatment reviews. 2013 May;39(3):219–29.  
131.  Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification 
negative breast cancer. Cancer discovery. 2013 Feb;3(2):224–37.  
132.  Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor 
cells: activation of AXL. Cancer research. 2009 Sep;69(17):6871–8.  
133.  Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase 
inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proceedings of the National 
Academy of Sciences. 2006 May;103(20):7795–800.  
134.  Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an 
orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the 
treatment of cancer. Bioorganic & medicinal chemistry letters. 2001 Jul;11(14):1911–4.  
135.  Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal 
growth factor signaling with potential for cancer therapy. Cancer research. 2002 Oct;62(20):5749–54.  
136.  Sharma S V, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. 
Nature reviews Cancer. Nature Publishing Group; 2007 Mar;7(3):169–81.  
137.  Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung 
cancer: biological and clinical implications. Cancer research. 2004 Dec;64(24):8919–23.  
138.  Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer 
to gefitinib. The New England journal of medicine. 2005 Feb;352(8):786–92.  
139.  Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib 
is associated with a second mutation in the EGFR kinase domain. PLoS medicine. 2005 Mar;2(3):e73.  
140.  Yun C-H, Mengwasser KE, Toms A V, et al. The T790M mutation in EGFR kinase causes drug 
resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the 
United States of America. 2008 Feb;105(6):2070–5.  
141.  Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent 
acquired resistance to gefitinib. Proceedings of the National Academy of Sciences of the United States of 
America. 2005 May;102(21):7665–70.  
142.  Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in 
epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase 
inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 
2006 Nov;12(21):6494–501.  
143.  Tokumo M, Toyooka S, Ichihara S, et al. Double mutation and gene copy number of EGFR in gefitinib 
refractory non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2006 Jul;53(1):117–21.  
144.  Xu Y, Liu H, Chen J, et al. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase 
inhibitors gefitinib and erlotinib. Cancer Biology & Therapy. Landes Bioscience; 2010 Apr;9(8):572–82.  
145.  Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor 
receptor by cetuximab. Cancer cell. 2005 Apr;7(4):301–11.  
146.  Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody 
cetuximab. Cancer biology & therapy. 2011 May;11(9):777–92.  
147.  Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in 
metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British journal of cancer. 2007 
Apr;96(8):1166–9.  
148.  De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is 
associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Annals 
of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008 
Mar;19(3):508–15.  
149.  Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients 
with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology. 2008 Apr;26(10):1626–34.  
150.  Diaz LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR 
blockade in colorectal cancers. Nature. 2012 Jun 28 [cited 2013 Aug 7];486(7404):537–40.  
151.  Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR 
therapy in colorectal cancer. Nature. 2012 Jun 28 [cited 2013 Aug 7];486(7404):532–6.  
152.  Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to 
panitumumab or cetuximab in metastatic colorectal cancer. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology. 2008 Dec;26(35):5705–12.  
153.  Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated 
with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69(5):1851–7.  
154.  Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR 
therapies in colorectal cancer. Cancer discovery. 2013 Jun [cited 2013 Aug 10];3(6):658–73.  
155.  Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal 
growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer 
research. 2001 Jul;61(13):5090–101.  
156.  Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth 
factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal 
growth factor receptor therapy. Clinical cancer research : an official journal of the American Association 
for Cancer Research. 2004 Jan;10(2):784–93.  
157.  Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 
Jun;417(6892):949–54.  
158.  Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent 
antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of 
America. 2008 Feb;105(8):3041–6.  
159.  Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK 
pathway and enhance growth. Nature. 2010 Mar;464(7287):431–5.  
160.  Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. 
The New England journal of medicine. 2010 Aug;363(9):809–19.  
161.  Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF 
V600 mutations. The New England journal of medicine. 2012 Nov [cited 2013 Aug 10];367(18):1694–
703.  
162.  Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK 
or N-RAS upregulation. Nature. 2010 Dec;468(7326):973–7.  
163.  Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to 
vemurafenib in patients with metastatic melanoma. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2013 May 10 [cited 2013 Aug 10];31(14):1767–74.  
164.  Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF 
inhibitors through HGF secretion. Nature. 2012 Jul;487(7408):500–4.  
165.  Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition 
through feedback activation of EGFR. Nature. 2012 Mar;483(7387):100–3.  
166.  Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-
small-cell lung cancer. Nature. Nature Publishing Group; 2007 Aug;448(7153):561–6.  
167.  Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4-ALK non-small cell lung 
cancer. European journal of cancer (Oxford, England : 1990). 2010 Jul;46(10):1773–80.  
168.  Peters S, Taron M, Bubendorf L, et al. Treatment and detection of ALK-rearranged NSCLC. Lung 
Cancer. 2013 Jun;null(null).  
169.  Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel 
inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell 
lymphoma. Molecular cancer therapeutics. 2007 Dec;6(12 Pt 1):3314–22.  
170.  Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits 
cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer 
research. 2007 May;67(9):4408–17.  
171.  Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to 
ALK inhibitors. The New England journal of medicine. 2010 Oct;363(18):1734–9.  
172.  Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-
rearranged lung Cancers. Science translational medicine. 2012 Feb;4(120):120ra17.  
173.  Tanizaki J, Okamoto I, Okabe T, et al. Activation of HER family signaling as a mechanism of acquired 
resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clinical cancer 
research : an official journal of the American Association for Cancer Research. 2012 Nov;18(22):6219–
26.  
174.  Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human 
cancers. Science (New York, NY). 2004 Apr;304(5670):554.  
175.  Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 
2006;94(4):455–9.  
176.  Janku F, Wheler JJ, Naing A, et al. PIK3CA mutation H1047R is associated with response to 
PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer research. 2013 
Jan;73(1):276–84.  
177.  Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR Inhibitors in Patients With Breast and 
Gynecologic Malignancies Harboring PIK3CA Mutations. Journal of Clinical Oncology. 2012 
Jan;30(8):777–82.  
178.  Marone R, Cmiljanovic V, Giese B, et al. Targeting phosphoinositide 3-kinase: moving towards therapy. 
Biochimica et biophysica acta. 2008 Jan;1784(1):159–85.  
179.  Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of 
AKT1 in cancer. Nature. 2007;448(7152):439–44.  
180.  Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature 
reviews Cancer. 2002 Jul;2(7):489–501.  
181.  McMillan R, Matsui W. Molecular pathways: the hedgehog signaling pathway in cancer. Clinical cancer 
research : an official journal of the American Association for Cancer Research. 2012 Sep;18(18):4883–8.  
182.  Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. 
Nature. 2008 Sep;455(7211):406–10.  
183.  Coni S, Infante P, Gulino A. Control of stem cells and cancer stem cells by Hedgehog signaling: 
pharmacologic clues from pathway dissection. Biochemical pharmacology. 2013 Mar;85(5):623–8.  
184.  Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell 
carcinoma. The New England journal of medicine. 2012 Jun;366(23):2171–9.  
185.  Yauch RL, Dijkgraaf GJP, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog 
pathway inhibitor in medulloblastoma. Science (New York, NY). 2009 Oct;326(5952):572–4.  
186.  Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by 
inhibition of the PI3K pathway in medulloblastoma. Science translational medicine. 2010 
Sep;2(51):51ra70.  
187.  Dijkgraaf GJP, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory 
smoothened mutants and downstream mechanisms of drug resistance. Cancer research. 2011 
Jan;71(2):435–44.  
 
